Loading…
Loading…
CNGGF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CNGGF and 80,000+ other tickers.
See exactly how CNGGF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CNGGF and 80,000+ other tickers.
Cann Group Limited specializes in the end-to-end process of bringing medicinal cannabis to market. Its activities span from genetic development and cultivation to product manufacturing, clinical trials, and ultimately, the supply of therapeutic cannabis for both Australian consumption and international export. The company holds specific licenses enabling it to conduct research and grow cannabis for human medicinal and scientific study. Founded in 2014, Cann Group Limited operates out of its base in Port Melbourne, Australia.
Cann Group Limited (OTCPK:CNGGF) Shareholder/Analyst Call November 4, 2025 6:15 PM EST Company Participants Jennifer Pilcher - CEO, MD & Executive Director Mike Ryan Presentation Jennifer Pilcher CEO, MD & Executive Director All right. Welcome to today's webinar, everybody.
Company Announces Launch of Prodigy Health Plus ORLANDO, FL / ACCESSWIRE / July 9, 2024 / Cann America Corp. (OTC PINK:CNNA), the "Company", and the parent company of subsidiaries, Prodigy Health Plus and Prodigy Stem Cell (collectively known as "Prodigy Elite Group"), is excited to announce the official launch of Prodigy Health Plus, a crucial component of its comprehensive suite of healthcare products. The launch marks the beginning of a series of product releases.
Cann Group Limited (OTCPK:CNGGF) Q2 2023 Earnings Conference Call February 27, 2023 7:00 PM ET Company Participants Matt Wright - NWR Communications Allan McCallum - Chairman Peter Crock - CEO Deborah Ambrosini - CFO Conference Call Participants Matt Wright Thank you for standing by, and welcome to the Cann Group Half Year Results Investor Webinar for FY'23. All participants are in a listen-only mode.
Cann Gr (OTC:CNGGF) shares closed up 5.84% at $0.21 with an estimated market cap of $66.8M. Cansortium (OTC:CNTMF) shares closed up 4.75% at $0.64 with an estimated market cap of $141.3M.